NCT07347288

SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma

An Open-label, Multicenter Exploratory Clinical Study of the EZH2 Inhibitor SHR2554 as Maintenance Therapy After First-line Systemic Treatment in Patients With Peripheral T-cell Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the Safety and Efficacy of SHR2554 as Maintenance Therapy after first-line systemic treatment in patients with peripheral T-cell lymphoma

Conditions

• PTCL

Interventions

Type	Name	Description
DRUG	SHR2554 Tablets	SHR2554 orally twice daily

Timeline

• Start date: 2026-02-01
• Primary completion: 2029-02-01
• Completion: 2029-06-01
• First posted: 2026-01-16
• Last updated: 2026-01-16

Locations

1 site across 1 country: China